RNA (Epi)genetics in cardiovascular diseases

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 11-16

  Elia, Leonardo ^a,b   Condorelli, Gianluigi ^a,b,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Milan Unit   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular diseases; Long non coding RNAs; MicroRNAs; RNA therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 122; MICRORNA 34A; MRX 34; PIWI INTERACTING RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

CANCER THERAPY; CARDIOVASCULAR DISEASE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; RNA SEQUENCE; RNA SPLICING; TRANSCRIPTION REGULATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; EPIGENESIS, GENETIC; HUMANS; RNA, LONG NONCODING; RNA, UNTRANSLATED;

EID: 84952715101     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.07.012     Document Type: Review

References (82)

1. Amaral P.P., Dinger M.E., Mercer T.R., Mattick J.S. The eukaryotic genome as an RNA machine. Science 2008, 319:1787-1789.
2. Collins L.J., Chen X.S. Ancestral RNA: the RNA biology of the eukaryotic ancestor. RNA Biol. 2009, 6:495-502.
3. Collins L.J., Penny D. The RNA infrastructure: dark matter of the eukaryotic cell?. Trends Genet. 2009, 25:120-128.
4. Mattick J.S. Deconstructing the dogma: a new view of the evolution and genetic programming of complex organisms. Ann. N. Y. Acad. Sci. 2009, 1178:29-46.
5. Mattick J.S. The genetic signatures of noncoding RNAs. PLoS Genet. 2009, 5:e1000459.
6. Kurokawa R., Rosenfeld M.G., Glass C.K. Transcriptional regulation through noncoding RNAs and epigenetic modifications. RNA Biol. 2009, 6:233-236.
7. Shrey K., Suchit A., Nishant M., Vibha R. RNA interference: emerging diagnostics and therapeutics tool. Biochem. Biophys. Res. Commun. 2009, 386:273-277.
8. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
10. Eulalio A., Huntzinger E., Nishihara T., Rehwinkel J., Fauser M., Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15:21-32.
11. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1608-1613.
12. Qu H., Zheng L., Pu J., Mei H., Xiang X., Zhao X., et al. miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum. Mol. Genet. 2015, 24:2539-2551.
13. Zhang Y., Fan M., Zhang X., Huang F., Wu K., Zhang J., et al. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs. RNA 2014, 20:1878-1889.
14. Latronico M.V., Elia L., Condorelli G., Catalucci D. Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int. J. Biochem. Cell Biol. 2008, 40:1643-1648.
15. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13:613-618.
16. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008, 22:3242-3254.
17. Castaldi A., Zaglia T., Di Mauro V., Carullo P., Viggiani G., Borile G., et al. MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade. Circ. Res. 2014, 115:273-283.
18. Elia L., Contu R., Quintavalle M., Varrone F., Chimenti C., Russo M.A., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120:2377-2385.
19. Zhao Y., Samal E., Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220.
20. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 2007, 13:486-491.
21. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 2010, 106:1675-1680.
22. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 2010, 225:631-637.
23. Liang H., Zhang C., Ban T., Liu Y., Mei L., Piao X., et al. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int. J. Biochem. Cell Biol. 2012, 44:2152-2160.
24. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
25. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
26. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13027-13032.
27. Suarez Y., Fernandez-Hernando C., Pober J.S., Sessa W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007, 100:1164-1173.
28. Suarez Y., Fernandez-Hernando C., Yu J., Gerber S.A., Harrison K.D., Pober J.S., et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14082-14087.
29. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-284.
30. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
31. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
32. Hergenreider E., Heydt S., Treguer K., Boettger T., Horrevoets A.J., Zeiher A.M., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell Biol. 2012, 14:249-256.
33. Kohlstedt K., Trouvain C., Boettger T., Shi L., Fisslthaler B., Fleming I. AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ. Res. 2013, 112:1150-1158.
34. Akao Y., Nakagawa Y., Kitade Y., Kinoshita T., Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007, 98:1914-1920.
35. Michael M.Z., SM OC, van Holst Pellekaan N.G., Young G.P., James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 2003, 1:882-891.
36. Cordes K.R., Sheehy N.T., White M.P., Berry E.C., Morton S.U., Muth A.N., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460:705-710.
37. Quintavalle M., Elia L., Condorelli G., Courtneidge S.A. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J. Cell Biol. 2010, 189:13-22.
38. Cheng Y., Liu X., Yang J., Lin Y., Xu D.Z., Lu Q., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 2009, 105:158-166.
39. Boettger T., Beetz N., Kostin S., Schneider J., Kruger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 2009, 119:2634-2647.
40. Elia L., Quintavalle M., Zhang J., Contu R., Cossu L., Latronico M.V., et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009, 16:1590-1598.
41. Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F., et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009, 23:2166-2178.
42. Torella D., Iaconetti C., Catalucci D., Ellison G.M., Leone A., Waring C.D., et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ. Res. 2011, 109:880-893.
43. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
44. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
45. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2009, 2:ra81.
46. Zhou J., Li Y.S., Nguyen P., Wang K.C., Weiss A., Kuo Y.C., et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ. Res. 2013, 113:40-51.
47. Climent-Salarich M., Quintavalle M., Miragoli M., Chen J., Condorelli G., Elia L. TGFbeta triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ. Res. 2015, 116(11):1753-1764.
48. Guttman M., Amit I., Garber M., French C., Lin M.F., Feldser D., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458:223-227.
49. Khalil A.M., Guttman M., Huarte M., Garber M., Raj A., Rivea Morales D., et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11667-11672.
50. Anderson D.M., Anderson K.M., Chang C.L., Makarewich C.A., Nelson B.R., McAnally J.R., et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 2015, 160:595-606.
51. Magny E.G., Pueyo J.I., Pearl F.M., Cespedes M.A., Niven J.E., Bishop S.A., et al. Conserved regulation of cardiac calcium uptake by peptides encoded in small open reading frames. Science 2013, 341:1116-1120.
52. Ng S.Y., Johnson R., Stanton L.W. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J. 2012, 31:522-533.
53. Zhao J., Sun B.K., Erwin J.A., Song J.J., Lee J.T. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008, 322:750-756.
54. Nagano T., Mitchell J.A., Sanz L.A., Pauler F.M., Ferguson-Smith A.C., Feil R., et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008, 322:1717-1720.
55. Orom U.A., Derrien T., Beringer M., Gumireddy K., Gardini A., Bussotti G., et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010, 143:46-58.
56. Carrieri C., Cimatti L., Biagioli M., Beugnet A., Zucchelli S., Fedele S., et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature 2012, 491:454-457.
57. Yoon J.H., Abdelmohsen K., Srikantan S., Yang X., Martindale J.L., De S., et al. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 2012, 47:648-655.
58. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
59. Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495:384-388.
60. Memczak S., Jens M., Elefsinioti A., Torti F., Krueger J., Rybak A., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495:333-338.
61. Klattenhoff C.A., Scheuermann J.C., Surface L.E., Bradley R.K., Fields P.A., Steinhauser M.L., et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 2013, 152:570-583.
62. Wang K.C., Yang Y.W., Liu B., Sanyal A., Corces-Zimmerman R., Chen Y., et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011, 472:120-124.
63. Lee J.T., Davidow L.S., Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre. Nat. Genet. 1999, 21:400-404.
64. Warshawsky D., Stavropoulos N., Lee J.T. Further examination of the Xist promoter-switch hypothesis in X inactivation: evidence against the existence and function of a P(0) promoter. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14424-14429.
65. Grote P., Wittler L., Hendrix D., Koch F., Wahrisch S., Beisaw A., et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev. Cell 2013, 24:206-214.
66. Lin R., Roychowdhury-Saha M., Black C., Watt A.T., Marcusson E.G., Freier S.M., et al. Control of RNA processing by a large non-coding RNA over-expressed in carcinomas. FEBS Lett. 2011, 585:671-676.
67. Hutchinson J.N., Ensminger A.W., Clemson C.M., Lynch C.R., Lawrence J.B., Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007, 8:39.
68. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
69. Vicens Q., Westhof E. Biogenesis of circular RNAs. Cell 2014, 159:13-14.
70. Li Z., Huang C., Bao C., Chen L., Lin M., Wang X., et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 2015, 22:256-264.
71. Zhang X.O., Wang H.B., Zhang Y., Lu X., Chen L.L., Yang L. Complementary sequence-mediated exon circularization. Cell 2014, 159:134-147.
72. Ashwal-Fluss R., Meyer M., Pamudurti N.R., Ivanov A., Bartok O., Hanan M., et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 2014, 56:55-66.
73. Hansen T.B., Wiklund E.D., Bramsen J.B., Villadsen S.B., Statham A.L., Clark S.J., et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J. 2011, 30:4414-4422.
74. Eulalio A., Mano M., Dal Ferro M., Zentilin L., Sinagra G., Zacchigna S., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492:376-381.
75. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
76. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19:1116-1122.
77. Montgomery R.L., Yu G., Latimer P.A., Stack C., Robinson K., Dalby C.M., et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol. Med. 2014, 6:1347-1356.
78. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
79. Wheeler T.M., Leger A.J., Pandey S.K., MacLeod A.R., Nakamori M., Cheng S.H., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488:111-115.
80. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
81. Janssen H.L., Reesink H.W., Zeuzem S., Lawitz E., Rodriguez-Torres M., Chen A., et al. A randomized, double-blind, placebo (Plb) controlled safety and anti-viral proof of concept study of Miravirsen (Mir), an oligonucleotide targeting Mir-122, in treatment naive patients with genotype 1 (Gt1) chronic Hcv infection. Hepatology 2011, 54:1430a-a.
82. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.